Literature DB >> 29139018

Vaccination Against Hydatidosis: Molecular Cloning and Optimal Expression of the EG95NC- Recombinant Antigen in Escherichia coli.

M Jazouli1,2,3, M Lightowlers4, C G Gauci4, K Tadlaoui5, A Belmlih5, M M Ennaji6, M Elharrak5.   

Abstract

Cystic echinococcosis (CE) is a widely distributed zoonosis that is highly endemic in the Mediterranean basin. The disease represents a serious public health threat and causes economic losses. The parasite life-cycle involves dogs and ruminants as definitive and intermediate hosts; humans are accidently infected, causing serious clinical issues. Vaccination of ruminants and dog treatments represent the most efficient measures to prevent parasite transmission. The recombinant protein vaccine, EG95, has been used successfully in sheep vaccine trials against CE in several countries. In this study, we expressed the modified antigen, EG95NC-GST, in Escherichia coli for use as a vaccine against Echinococcus granulosus in ruminants. We tested three different media formulations for E. coli culture and established for each culture conditions for optimal levels of soluble EG95 expression. The results demonstrate that SOC and TB media provided high yields in cell density and EG95 protein expression. Purification of the recombinant protein with affinity chromatography (using FPLC) was also performed to increase the purity of the EG95NC--GST antigen.

Entities:  

Keywords:  Echinococcus granulosus; Escherichia coli; Hydatidosis; Recombinant protein; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 29139018     DOI: 10.1007/s10930-017-9742-x

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  15 in total

1.  Production characteristics of interferon-alpha using an L-arabinose promoter system in a high-cell-density culture.

Authors:  H K Lim; K H Jung; D H Park; S I Chung
Journal:  Appl Microbiol Biotechnol       Date:  2000-02       Impact factor: 4.813

2.  Vaccination against hydatidosis using a defined recombinant antigen.

Authors:  M W Lightowlers; S B Lawrence; C G Gauci; J Young; M J Ralston; D Maas; D D Heath
Journal:  Parasite Immunol       Date:  1996-09       Impact factor: 2.280

3.  Special issue: Experimental studies in echinococcosis.

Authors:  Andrew Hemphill; Peter Kern
Journal:  Exp Parasitol       Date:  2008-05-03       Impact factor: 2.011

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Simple fed-batch technique for high cell density cultivation of Escherichia coli.

Authors:  D J Korz; U Rinas; K Hellmuth; E A Sanders; W D Deckwer
Journal:  J Biotechnol       Date:  1995-02-21       Impact factor: 3.307

6.  Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep.

Authors:  M W Lightowlers; O Jensen; E Fernandez; J A Iriarte; D J Woollard; C G Gauci; D J Jenkins; D D Heath
Journal:  Int J Parasitol       Date:  1999-04       Impact factor: 3.981

7.  A recombinant vaccine against hydatidosis: production of the antigen in Escherichia coli.

Authors:  Daniel Manderson; Robert Dempster; Yusuf Chisti
Journal:  J Ind Microbiol Biotechnol       Date:  2005-09-30       Impact factor: 3.346

Review 8.  Echinococcosis: a review.

Authors:  Pedro Moro; Peter M Schantz
Journal:  Int J Infect Dis       Date:  2008-10-19       Impact factor: 3.623

9.  Expression of ovine gamma interferon in Escherichia coli and Corynebacterium glutamicum.

Authors:  H Billman-Jacobe; A L Hodgson; M Lightowlers; P R Wood; A J Radford
Journal:  Appl Environ Microbiol       Date:  1994-05       Impact factor: 4.792

10.  Epidemiological study of the cystic echinococcosis in Morocco.

Authors:  Rkia Azlaf; Allal Dakkak
Journal:  Vet Parasitol       Date:  2006-02-10       Impact factor: 2.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.